Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Journal of Family Therapy|April 6, 2021
Facilitator lessons from online psychoeducational group for relational well-being in India during COVID-19 pandemicAparna Joshi, Amrita Joshi, Ipsita Chatterjee, et al.
Medical Journal, Armed Forces India|November 20, 2023
Corneal transplantation: A walk to visionS K Mishra, Amrita Joshi, P M Ginu, et al.
European Journal of Immunology|July 16, 2008
CC chemokine receptor 4 modulates Toll-like receptor 9-mediated innate immunity and signalingMakoto Ishii, Cory M Hogaboam, Amrita Joshi, et al.
Medical Journal, Armed Forces India|May 11, 2026
Epithelial ingrowth post small incision lenticule extraction: CIRCLE software to the rescueSupriya Dhar, S K Mishra, Navjyot Kaur, et al.
Cellular Immunology|March 1, 2017
Enhancement of macrophage inflammatory responses by CCL2 is correlated with increased miR-9 expression and downregulation of the ERK1/2 phosphatase Dusp6William F Carson, Sarah E Salter-Green, Melissa M Scola, et al.
International Journal of Retina and Vitreous|July 28, 2022
Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patientsSanjay Kumar Mishra, Pradeep Kumar, Srishti Khullar, et al.
Indian Journal of Ophthalmology|April 17, 2025
Microkeratome-assisted vs femtosecond laser-assisted superficial anterior lamellar keratoplasty: A randomized controlled trialSanjay Kumar Mishra, Mrinalini Singh, Amrita Joshi, et al.
Indian Journal of Ophthalmology|May 27, 2026
Ultrawide-field indocyanine angiography changes post 12 weeks of eplerenone in central serous chorioretinopathyAketi Sagar, Sanjay Mishra, Pradeep Kumar, et al.
Indian Journal of Ophthalmology|June 22, 2026
A randomized controlled study to compare the efficacy of intravitreal faricimab 6.0 mg versus aflibercept 2.0 mg in management of treatment-naive diabetic macular edema in Indian populationsSanjay Mishra, Mrida Dutt, Pradeep Kumar, et al.
International Journal of Retina and Vitreous|January 13, 2025
Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edemaSanjay Kumar Mishra, Pradeep Kumar, Amrita Joshi, et al.
Pageof 3